NYSE · Biotech stocks database
BMY (Bristol-Myers Squibb Company) stock: $62.13, $127.01B market cap, $12.96B cash, $156.93B EV, $126.91B fully diluted market cap. Data from Fully Diluted's biotech stocks database.
We operate in a single segment engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of innovative medicines that help patients prevail over serious diseases. Our principal strategy is to combine the resources, scale and capability of a large pharmaceutical company with the speed, agility and focus on innovation typically found in the biotech industry.
Source: 10-K FY2025 via SEC EDGAR
| Cash | $12,959.0M |
|---|---|
| Debt | $42,877.0M |
| Net cash | -$29,918.0M |
| Enterprise value | $156,927.3M |
| Basic shares | 2,042.7M shares |
| Fully diluted shares | 2,042.7M shares |
| Fully diluted market cap | $126,913.9M |
| Cash per share | $6.34 |
| Quarterly burn | +$3,393.0M generated |
Cash figures as of 2026-09-30. Database snapshot: 2026-11-07.
Cap table as of 2026-10-21.
Loading BMY daily closes…
Navlimetostat · Now - Nov 23, 2026 Now · Phase 1 · Healthy Participants
| Expected | Drug | Phase | Indication | Mgmt guide |
|---|---|---|---|---|
| Now - Nov 23, 2026 Now | Navlimetostat | Phase 1 | Healthy Participants | — |
| Now - Nov 28, 2026 Now | BMS-986490 | Phase 2 | Advanced Solid Tumors | — |
| Nov 11 - Dec 23 in 4d | BMS-986449 | Phase 2 | Advanced Solid Tumors | — |
| Nov 16 - Dec 28 in 9d | KarXT | Phase 3 | Psychosis Associated With Alzheimer's Disease | — |
| Nov 23, 2026 - Jan 4, 2027 in 16d | CC-92480 | Phase 2 | Multiple Myeloma | — |
| Nov 23, 2026 - Jan 4, 2027 in 16d | Cabozantinib | Phase 2 | Castration-resistant Prostate Cancer; Metastatic Cancer | — |
| Nov 26, 2026 - Jan 7, 2027 in 19d | Milvexian | Phase 3 | Ischemic Stroke; Ischemic Attack, Transient | — |
| Nov 30, 2026 - Jan 11, 2027 in 23d | Deucravacitinib | Phase 3 | Systemic Lupus Erythematosus | — |
| Nov 30, 2026 - Jan 11, 2027 in 23d | Deucravacitinib | Phase 3 | Systemic Lupus Erythematosus | — |
| Dec 12, 2026 - Jan 23, 2027 in 5 wks | CC-122 | Phase 1 | Non-Hodgkin Lymphoma | — |
| Dec 13, 2026 - Jan 24, 2027 in 5 wks | KarXT | Phase 3 | Bipolar-I Disorder With Mania or Mania With Mixed Features | — |
| Dec 14, 2026 - Jan 25, 2027 in 5 wks | KarXT | Phase 3 | Bipolar Disorder Type I With Mania or Mania With Mixed Features | — |
| Dec 25, 2026 - Feb 5, 2027 in 7 wks | Nivolumab | Phase 2 | Melanoma | — |
| Dec 29, 2026 - Feb 9, 2027 in 7 wks | BMS-985521 | Phase 1 | Healthy Volunteers | — |
| Dec 30, 2026 - Feb 10, 2027 in 8 wks | Deucravacitinib | Phase 3 | Sjögren's Syndrome | — |
| Jan 5 - Feb 16 in 8 wks | KarXT | Phase 3 | Alzheimer Disease | — |
| Jan 11 - Feb 22 in 9 wks | RP3 | Phase 1 | Advanced Solid Tumor | — |
| Jan 12 - Feb 23 in 9 wks | TJ033721 (givastomig) | Phase 1 | Solid Tumor; Advanced Cancer; Metastatic Cancer | — |
| Jan 16 - Feb 27 in 10 wks | Navlimetostat | Phase 1 | Healthy Female Participants | — |
| Jan 19 - Mar 2 in 10 wks | Milvexian | Phase 3 | Atrial Fibrillation | — |
| Jan 20 - Mar 3 in 11 wks | KarXT | Phase 3 | Psychosis Associated With Alzheimer's Disease | — |
| Jan 25 - Mar 8 in 11 wks | BMS-986435 | Phase 2 | Heart Failure | — |
| Jan 25 - Mar 8 in 11 wks | Golcadomide | Phase 1 | Kidney Failure, Chronic | — |
| Jan 28 - Mar 11 in 12 wks | BMS-986435 | Phase 1 | Healthy Volunteers | — |
| Jan 31 - Mar 14 in 12 wks | Cabozantinib | Phase 2 | Papillary Renal Cell Carcinoma; Unclassified Renal Cell Carcinoma; Translocation Renal Cell Carcinoma | — |
| Feb 7 - Mar 21 in 13 wks | BMS-986521 | Phase 1 | Healthy Volunteers | — |
| Feb 10 - Mar 24 in 14 wks | Nivolumab | Phase 1 | Glioblastoma; GBM; Glioblastoma Multiforme | — |
| Feb 17 - Mar 31 in 15 wks | BMS-986470 | Phase 2 | Anemia, Sickle Cell; Healthy Volunteers | — |
| Mar 2 - Apr 13 in 16 wks | BMS-986504 | Phase 1 | Advanced Solid Tumors | — |
| Mar 13 - Apr 24 in 4 mo | BMS-986369 | Phase 2 | Relapsed or Refractory T-cell Lymphomas | — |
| Mar 15 - Apr 26 in 4 mo | BMS-986497 | Phase 1 | Acute Myeloid Leukemia; Myelodysplastic Syndrome | — |
| Mar 15 - Apr 26 in 4 mo | Tazemetostat | Phase 2 | Atypical Teratoid Rhabdoid Tumor; INI1 (SMARCB1)-Deficient Primary CNS Malignant Tumors; SMARCA4-deficient Primary CNS Malignant Tumors | — |
| Mar 19 - Apr 30 in 4 mo | Nivolumab | Phase 2 | Non-Small Cell Lung Cancer | — |
| Apr 22 - Jun 3 in 6 mo | Nivolumab | Phase 3 | Renal Cell Carcinoma | — |
| GUIDEDMay 13, 2027 in 6 mo | mezigdomide NDA PDUFA in relapsed/refractory multiple myeloma | Not disclosed | relapsed/refractory multiple myeloma | May 13, 2027 |
| Apr 29 - Jun 10 in 6 mo | BMS-986446 | Phase 2 | Alzheimer Disease, Early Onset | — |
| May 6 - Jun 17 in 6 mo | Navlimetostat | Phase 1 | Healthy Female Adults | — |
| May 10 - Jun 21 in 6 mo | Xanomeline Enteric Capsule | Phase 1 | Healthy Volunteers | — |
| May 13 - Jun 24 in 6 mo | Selinexor | Phase 2 | Multiple Myeloma | — |
| Jul 7 - Aug 18 in 8 mo | BMS-986489 | Phase 1 | Small Cell Lung Carcinoma | — |
| Jul 13 - Aug 24 in 8 mo | BMS-986533 | Phase 1 | Healthy Volunteers | — |
| Jul 29 - Sep 9 in 9 mo | BMS-986446 | Phase 1 | Alzheimer's Disease; Healthy Participants | — |
| Aug 2 - Sep 13 in 9 mo | KarXT | Phase 1 | Schizophrenia | — |
| Aug 9 - Sep 20 in 9 mo | BMS-986454 | Phase 1 | Rheumatoid Arthritis | — |
| Aug 27 - Oct 8 in 10 mo | Luspatercept | Phase 2 | Anemia | — |
| Oct 19 - Nov 30 in 12 mo | KarXT | Phase 3 | Psychosis Associated With Alzheimer's Disease | — |
| Nov 25, 2027 - Jan 6, 2028 in 13 mo | BMS-986484 | Phase 1 | Advanced Solid Tumors | — |
| Nov 26, 2027 - Jan 7, 2028 in 13 mo | BMS-986488 | Phase 1 | Advanced Malignant Tumors | — |
| Dec 6, 2027 - Jan 17, 2028 in 13 mo | BMS-986504 | Phase 1 | Advanced Solid Tumors With Homozygous MTAP Deletion | — |
| Dec 9, 2027 - Jan 20, 2028 in 13 mo | BMS-986458 | Phase 2 | Relapsed/Refractory Non-Hodgkin Lymphoma | — |
| Dec 28, 2027 - Feb 8, 2028 in 14 mo | Elranatamab | Phase 1 | Multiple Myeloma | — |
| Jan 12 - Feb 23 in 14 mo | Pumitamig | Phase 2 | Pancreatic Ductal Adenocarcinoma (PDAC) | — |
| Jan 21 - Mar 3 in 15 mo | MRTX1719 | Phase 1 | Mesothelioma; Non Small Cell Lung Cancer; Malignant Peripheral Nerve Sheath Tumors | — |
| Feb 7 - Mar 20 in 15 mo | BMS-986278 | Phase 3 | Progressive Pulmonary Fibrosis | — |
| Feb 10 - Mar 23 in 15 mo | BMS-986393 | Phase 3 | Relapsed or Refractory Multiple Myeloma (RRMM) | — |
| Feb 11 - Mar 24 in 15 mo | NeoVax | Phase 1 | Kidney Cancer | — |
| Feb 11 - Mar 24 in 15 mo | Cohort A1 & A2: KTX-1001 | Phase 1 | Multiple Myeloma; Myeloma; Myeloma Multiple | — |
| Feb 11 - Mar 24 in 15 mo | Hyperpolarized Bicarbonate (13C) | Early Phase 1 | Prostate Cancer; Localized Prostate Carcinoma | — |
| Feb 12 - Mar 25 in 15 mo | Pumitamig | Phase 2 | Recurrent Glioblastoma | — |
| Feb 20 - Apr 2 in 16 mo | Rituximab | Phase 2 | Lymphoma | — |
| Apr 3 - May 15 in 17 mo | KarXT | Phase 3 | Alzheimer Disease; Psychosis | — |
| Apr 24 - Jun 5 in 18 mo | Iza-bren | Phase 3 | Breast Neoplasms | — |
| May 5 - Jun 16 in 18 mo | Luspatercept | Phase 3 | Myelodysplastic Syndromes | — |
| May 13 - Jun 24 in 18 mo | roginolisib | Phase 2 | Peripheral T Cells Lymphoma (PTCL) | — |
| May 18 - Jun 29 in 19 mo | BMS-986489 (Atigotatug | Phase 3 | Extensive-Stage Small Cell Lung Cancer | — |
| Jun 28 - Aug 9 in 20 mo | CC-97540 | Phase 2 | Lupus Erythematosus, Systemic; Lupus Nephritis | — |
| Jul 13 - Aug 24 in 20 mo | RP1 | Phase 2 | Non-Small Cell Lung Cancer (NSCLC); Microsatellite Instability-High (MSI-H); Non-melanoma Skin Cancer (NMSC) | — |
| Jul 25 - Sep 5 in 21 mo | KarXT | Phase 3 | Bipolar Disorder Type I With Mania | — |
| Sep 11 - Oct 23 in 22 mo | Oral Azacitidine | Phase 3 | Myelodysplastic Syndromes | — |
| Sep 11 - Oct 23 in 22 mo | BMS-986517 | Phase 2 | Solid Tumours | — |
| Sep 12 - Oct 24 in 22 mo | BMS-986393 | Phase 1 | Multiple Myeloma | — |
| Sep 12 - Oct 24 in 22 mo | BNT327 Dose Level 1 (DL1) | Phase 2 | Locally Advanced Breast Cancer; Triple Negative Breast Cancer; Metastatic Triple Negative Breast Cancers | — |
| Sep 26 - Nov 7 in 23 mo | BMS-986504 | Phase 2 | Solid Tumors | — |
| Oct 10 - Nov 21 in 23 mo | CC-97540 | Phase 1 | Systemic Lupus Erythematosus; Idiopathic Inflammatory Myopathy; Systemic Sclerosis | — |
| Oct 12 - Nov 23 in 24 mo | BMS-986158 | Phase 2 | Myelofibrosis | — |
| Oct 23 - Dec 4 in 24 mo | KarXT | Phase 3 | Alzheimer's Disease | — |
| Oct 23 - Dec 4 in 24 mo | KarXT | Phase 3 | Alzheimer's Disease | — |
| Oct 27 - Dec 8 in 24 mo | Pumitamig | Phase 2 | Locally Advanced Non-Small Cell Lung Cancer (NSCLC); Metastatic Non-Small Cell Lung Cancer (NSCLC) | — |
| Nov 4 - Dec 16 in 24 mo | KarXT | Phase 3 | Schizophrenia | — |
| Nov 24, 2028 - Jan 5, 2029 in 25 mo | BMS-986523 | Phase 2 | Advanced Solid Malignancies; Non-small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC) | — |
| Dec 15, 2028 - Jan 26, 2029 in 26 mo | Xanomeline Enteric Capsule | Phase 3 | Alzheimer's Disease | — |
| Dec 18, 2028 - Jan 29, 2029 in 26 mo | BMS-986511 | Phase 2 | Major Depressive Disorder | — |
| Dec 26, 2028 - Feb 6, 2029 in 26 mo | BMS-986353 | Phase 3 | Systemic Sclerosis | — |
| Jan 5 - Feb 16 in 26 mo | Xanomeline Enteric Capsule | Phase 3 | Alzheimer Disease | — |
| Jan 12 - Feb 23 in 27 mo | Pumitamig | Phase 3 | Extensive-stage Small-cell Lung Cancer | — |
| Jan 25 - Mar 8 in 27 mo | BMS-986500 | Phase 1 | Advanced Solid Tumor; Advanced Breast Cancer; Advanced Ovarian Cancer | — |
| Jan 26 - Mar 9 in 27 mo | Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | — |
| Jan 30 - Mar 13 in 27 mo | BMS-986463 | Phase 1 | High-grade Serous Ovarian Carcinoma (HGSOC); Uterine Serous Carcinoma (USC); Non-small Cell Lung Cancer (NSCLC) | — |
| Feb 9 - Mar 23 in 28 mo | BMS-986504 | Phase 2 | Carcinoma, Non-Small-Cell Lung | — |
| Feb 11 - Mar 25 in 28 mo | CC-97540 | Phase 2 | Antineutrophil Cytoplasmic Antibody-associated Vasculitis | — |
| Feb 12 - Mar 26 in 28 mo | Deucravacitinib | Phase 3 | Plaque Psoriasis | — |
| Feb 12 - Mar 26 in 28 mo | Pumitamig | Phase 3 | Non-small Cell Lung Cancer | — |
| Feb 15 - Mar 29 in 28 mo | BMS-986482 | Phase 2 | Advanced Solid Tumors | — |
| Mar 9 - Apr 20 in 28 mo | Iza-bren | Phase 3 | Urothelial Cancer | — |
| Mar 15 - Apr 26 in 29 mo | Administration of a combination of treatments | Phase 2 | Relapsed or Refractory Multiple Myeloma (RRMM) | — |
| Apr 12 - May 24 in 30 mo | Iberdomide | Phase 2 | Refractory Multiple Myeloma; Relapsed Multiple Myeloma | — |
| Apr 26 - Jun 7 in 30 mo | Iberdomide | Phase 3 | Multiple Myeloma | — |
| Apr 26 - Jun 7 in 30 mo | Fludarabine | Phase 1 | Refractory Autoimmune Diseases | — |
| Jun 4 - Jul 16 in 31 mo | BMS-986525 | Phase 2 | Relapsed/Refractory Small Cell Lung Cancer | — |
| Jun 14 - Jul 26 in 32 mo | Navlimetostat | Phase 3 | Pancreatic Ductal Adenocarcinoma | — |
| Aug 3 - Sep 14 in 33 mo | KarXT | Phase 3 | Alzheimer Disease; Agitation | — |
| Sep 17 - Oct 29 in 35 mo | KarXT | Phase 3 | Irritability Associated With Autism Spectrum Disorder | — |
| Sep 17 - Oct 29 in 35 mo | KarXT | Phase 3 | Irritability Associated With Autism Spectrum Disorder | — |
| Oct 5 - Nov 16 in 35 mo | BMS-986460 | Phase 1 | Metastatic Castration-resistant Prostate Cancer | — |
| Oct 6 - Nov 17 in 35 mo | Nivolumab | Phase 2 | Cancer | — |
| Nov 23, 2029 - Jan 4, 2030 in 37 mo | Deucravacitinib | Phase 3 | Plaque Psoriasis | — |
| Nov 26, 2029 - Jan 7, 2030 in 37 mo | Pumitamig | Phase 2 | Hepatocellular Carcinoma (HCC) | — |
| Dec 11, 2029 - Jan 22, 2030 in 38 mo | BMS-986528 | Phase 2 | Arthritis, Rheumatoid | — |
| Jan 3 - Feb 14 in 38 mo | BMS-986278 | Phase 3 | Pulmonary Fibrosis | — |
| Jan 9 - Feb 20 in 39 mo | Pumitamig | Phase 2 | Advanced Renal Cell Carcinoma (RCC) | — |
| Jan 12 - Feb 23 in 39 mo | Pumitamig | Phase 3 | Breast Neoplasms | — |
| Jan 29 - Mar 12 in 39 mo | KarXT | Phase 3 | Schizophrenia | — |
| Feb 11 - Mar 25 in 40 mo | Elotuzumab | Phase 2 | Myeloma; Multiple Myeloma; Refractory Multiple Myeloma | — |
| Mar 16 - Apr 27 in 41 mo | Pumitamig | Phase 3 | Untreated, Unresectable, or Metastatic Colorectal Cancer | — |
| Apr 17 - May 29 in 42 mo | Deucravacitinib | Phase 3 | Juvenile Psoriatic Arthritis | — |
| Apr 19 - May 31 in 42 mo | KarXT | Phase 3 | Schizophrenia; Autism-Related Irritability | — |
| Jun 13 - Jul 25 in 44 mo | BMS-986453 | Phase 1 | Relapsed and/or Refractory Multiple Myeloma | — |
| Jun 14 - Jul 26 in 44 mo | BMS-986506 | Phase 1 | Renal Cell Carcinoma | — |
| Jun 17 - Jul 29 in 44 mo | BMS-986353 | Phase 2 | Chronic Immune Thrombocytopenia; Autoimmune Hemolytic Anemia | — |
| Jul 12 - Aug 23 in 45 mo | Cabozantinib | Phase 3 | Cancer; Renal Cell Carcinoma (RCC); Pancreatic Neuroendocrine Tumors (pNET) | — |
| Sep 10 - Oct 22 in 47 mo | Nivolumab | Phase 3 | Non-small Cell Lung Cancer | — |
| Oct 30 - Dec 11 in 48 mo | Pumitamig | Phase 3 | Non-small Cell Lung Cancer (NSCLC) | — |
| Dec 12, 2030 - Jan 23, 2031 in 50 mo | Deucravacitinib | Phase 3 | Systemic Lupus Erythematosus; Sjögren's Disease; Psoriasis | — |
| Dec 20, 2030 - Jan 31, 2031 in 50 mo | Pumitamig | Phase 3 | Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, o | — |
| Feb 27 - Apr 10 in 52 mo | Deucravacitinib | Phase 3 | Plaque Psoriasis | — |
| Apr 9 - May 21 in 54 mo | BMS-986507 | Phase 2 | Lung Cancer; Breast Cancer | — |
| May 23 - Jul 4 in 55 mo | Ozanimod | Phase 3 | Multiple Sclerosis, Relapsing-Remitting | — |
| Sep 23 - Nov 4 in 59 mo | BMS-986504 | Phase 3 | Metastatic Non-small Cell Lung Cancer With MTAP Deletion | — |
| Oct 12 - Nov 23 in 60 mo | BMS-986340 | Phase 2 | Cervical Cancer; Gastric/Gastroesophageal Junction Adenocarcinoma; Microsatellite Stable Colorectal Cancer | — |
| Nov 25, 2031 - Jan 6, 2032 in 61 mo | Pumitamig | Phase 3 | Non-Small Cell Lung Cancer (NSCLC) | — |
| Feb 10 - Mar 23 in 64 mo | Iza-bren | Phase 3 | Non-Small Cell Lung Cancer | — |
| Jun 12 - Jul 24 in 68 mo | BMS-986489 | Phase 2 | Limited Stage Small Cell Lung Cancer | — |
| Aug 23 - Oct 4 in 71 mo | Ozanimod | Phase 3 | Colitis, Ulcerative | — |
| Feb 10 - Mar 24 in 76 mo | Belatacept | Phase 3 | Renal Allograft Recipients | — |
| May 13 - Jun 24 in 238 mo | DISP-10 | Phase 1 | Colorectal Cancer; Gastric Adenocarcinoma; Esophageal Adenocarcinoma | — |
Estimated readout windows: registry primary-completion date + 6-12 weeks. Windows already open are shown from "Now". Drug names link to ClinicalTrials.gov.
Per-asset detail extracted from the 10-Q filed 2026-07-30. Fields the filing does not state are marked "not disclosed" rather than filled from other sources.
No lead program on file for this company.
| Trial | Phase | Status | Role | Sponsor | BP | Condition(s) | Mgmt guide |
|---|---|---|---|---|---|---|---|
| NCT05511363 | Phase 3 | Recruiting | Sponsor | BMY | — | Psychosis Associated With Alzheimer's Disease | — |
| NCT06003426 | Phase 3 | Active, not recruiting | Sponsor | BMY | — | Idiopathic Pulmonary Fibrosis | — |
| NCT05617677 | Phase 3 | Active, not recruiting | Sponsor | BMY | — | Systemic Lupus Erythematosus | — |
| NCT05620407 | Phase 3 | Active, not recruiting | Sponsor | BMY | — | Systemic Lupus Erythematosus | — |
| NCT06951698 | Phase 3 | Recruiting | Sponsor | BMY | — | Bipolar-I Disorder With Mania or Mania With Mixed Features | — |
| NCT06951711 | Phase 3 | Recruiting | Sponsor | BMY | — | Bipolar Disorder Type I With Mania or Mania With Mixed Features | — |
| NCT05946941 | Phase 3 | Active, not recruiting | Sponsor | BMY | — | Sjögren's Syndrome | — |
| NCT06585787 | Phase 3 | Recruiting | Sponsor | BMY | — | Alzheimer Disease | — |
| NCT06126224 | Phase 3 | Recruiting | Sponsor | BMY | — | Psychosis Associated With Alzheimer's Disease | — |
| NCT03873402 | Phase 3 | Active, not recruiting | Sponsor | BMY | — | Renal Cell Carcinoma | — |
| NCT07140913 | Phase 3 | Recruiting | Sponsor | BMY | — | Mania; Bipolar Disorder | — |
| NCT05980949 | Phase 3 | Recruiting | Sponsor | BMY | — | Psychosis Associated With Alzheimer's Disease | — |
Sponsor-matched active trials from ClinicalTrials.gov (212 as sponsor, 238 as collaborator); "Sponsor" = company is the lead sponsor, "Collaborator" = company is a collaborator. The BP column flags big-pharma involvement as lead sponsor or collaborator (excluding the company itself). The Mgmt guide column shows what management guided for readout timing when a guided program matches the trial (hover for the quote, click for the source). Trial listings are not a company pipeline slide.
Tracked specialist funds: ADAR1 Capital Management, Aisling Capital, Ally Bridge Group, Avoro Capital Advisors, BVF Partners, Baker Bros. Advisors, Boxer Capital, Braidwell LP, Casdin Capital, Cormorant Asset Management, DAFNA Capital, Deerfield Management, EcoR1 Capital, Frazier Life Sciences, Great Point Partners, Ikarian Capital, Logos Global Management, OrbiMed Advisors, Perceptive Advisors, RA Capital Management, RTW Investments, Sphera Biotech, Stonepine Capital, Tang Capital Partners, Vivo Capital.
| Fund | Shares | Q/Q change | % of portfolio | Filing |
|---|---|---|---|---|
| OrbiMed Advisors | 925,000 | no change | 1.01% | 2026-08-14 |
| Sphera Biotech | 0 | -17,500 | 0.00% | 2026-08-14 |
| ADAR1 Capital Management | 0 | -17,500 | 0.00% | 2026-08-14 |
Specialist-fund positions from 13F filings. Q/Q change is vs the prior quarter's filing; % of portfolio is the fund's own reported portfolio weight.
Loading headlines…
Headlines from the Fully Diluted live wire: IR newsrooms, newswires, SEC filings, and halt notices, refreshed every 15 minutes.